BACKGROUND: @entity157 ( @entity157 ) conferring a grave prognosis may benefit from yttrium-90 ((90)Y) radioembolization. METHODS: Thirty @entity1 with advanced inoperable @entity157 including those with any lesion >8 cm in maximal diameter or multiple bi-lobar lesions (totally more than five lesions), or @entity715 treated with radioembolization were reviewed. Treatment efficacy and safety were evaluated. Univariate and multivariate analyses were performed for identifying potential prognostic factors. RESULTS: After a median follow-up of 18.3 months, the response rate was 30.0%, and the disease control rate was 50.0%. Median overall progression-free survival (PFS) and @entity1349 ( @entity1349 ) were 3.3 months and 13.2 months, respectively. Longer median PFS was noted in those who had transarterial chemoembolization before radioembolization (7.3 months vs 3.1 months; P=0.021) and duration of @entity1131 ( @entity1131 ) response >= 6 months (11.8 months vs 3.0 months; P<0.001). Longer median @entity1349 was also revealed in those without @entity715 (17.1 months vs 4.4 months; P=0.015) and those whose duration of @entity1131 response was >= 6 months (21.2 months vs 8.6 months; P=0.001). Seventeen @entity1 (56.7%) developed treatment-related complications including five (16.7%) grade 3 events. Multivariate analysis revealed that treatment responders (P=0.001) and duration of @entity1131 response >= 6 months (P=0.006) were prognostic of PFS, whereas the absence of portal vein invasion (P=0.025), treatment responders (P=0.010), and duration of @entity1131 response >= 6 months (P=0.001) were prognostic of @entity1349 . CONCLUSION: (90)Y radioembolization is an alternative treatment with a promising outcome for poor-risk advanced inoperable @entity157 .

Yttrium-90 radioembolization for advanced inoperable XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1131 :: ('MESH:D011488', 'Disease') :: ['AFP', 'alfafeto protein'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'Advanced inoperable hepatocellular carcinoma'] @entity715 :: ('MESH:D013927', 'Disease') :: ['portal vein thrombosis'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
